Welcome to the Pepper Lab

Based at Brighton and Sussex Medical School (BSMS)

The University of Sussex, UK.

A Sussex based research team hunting for novel cancer therapies.

Meet the team

What we do

We are a multi-disciplinary team that combines clinical and scientific skills to understand disease processes and identify novel therapeutic targets.

Patients

to obtain tumour cells

Experiments

to study tumour cell behaviour and identify novel targets

Collaborate

to design and manufacture novel drug

Drug Development

to test novel drugs in cancer cell models

Patients

the aim of our team is to improve patient prognosis and treatment

Meet the Team

Principal Investigators

Avatar

Andrea Pepper

Brighton and Sussex Medical School

Professor of Cancer Biology

Avatar

Chris Pepper

Brighton and Sussex Medical School

Professor of Cancer Research

Postdoctoral Researchers

Avatar

Emma Kennedy

Brighton and Sussex Medical School

Postdoctoral Researcher

Avatar

Tom Burley

Brighton and Sussex Medical School

Postdoctoral Researcher

PhD Students

Avatar

Eleni Ladikou

Brighton and Sussex Medical School

PhD Clinical Fellow

Avatar

Kim Sharp

Brighton and Sussex Medical School

PhD student

Administration

Avatar

Gemma Hamilton

Brighton and Sussex Medical School

Departmental Administrator

Projects

In vitro modelling and therapeutic targeting of tumour cell migration in chronic lymphocytic leukaemia.
This programme continuity grant is funded by Blood Cancer UK. Tumour cells migrate to protective niches in the body to avoid destruction by conventional therapies. We are modelling this in the laboratory in order to identify the mechanisms tumour cells use to migrate.
Modelling and targeting Acute Myeloid Leukaemia cells in the bone marrow protective niche
This project grant is funded by a British Society of Haematology start-up grant and the Sussex Cancer Fund. Acute Myeloid Leukaemia is an aggressive disease with poor survival outcomes. The tumour cells remain anchored in the protective niche of the bone marrow where they can avoid destruction by conventional therapies.
Overcoming ibrutinib and venetoclax resistance in chronic lymphocytic leukaemia.
This project grant is funded by the Medical Research Council (MRC). Ibrutinib and venetoclax have revolutionised treatment of chronic lymphocytic leukaemia (CLL). However, they are non-curative and some patients remain refractory or develop resistance.
Preferential stem cell targeting using ProTide nucleoside analogues
This project grant is funded by the pharmaceutical company, Nucana. Although conventional anti-cancer approaches can frequently eradicate a large proportion of the bulk tumour, the most primitive stem cells are frequently chemo-resistant.

Recent Publications

For links to all the recent publications from the team please click on the links below:

Andrea's publications

Chris's publications

Contact